William C Vesperman

Array ( [id] => 18359412 [patent_doc_number] => 20230141003 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-11 [patent_title] => BASELINE SERUM AUTOANTIBODIES FOR PREDICTING RECURRENCE AND TOXICITY FOR IMMUNE CHECKPOINT BLOCKADE IN CANCER PATIENTS [patent_app_type] => utility [patent_app_number] => 18/054043 [patent_app_country] => US [patent_app_date] => 2022-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26616 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18054043 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18391428 [patent_doc_number] => 20230159646 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-25 [patent_title] => ANTI-CD-25 ANTIBODY [patent_app_type] => utility [patent_app_number] => 17/821295 [patent_app_country] => US [patent_app_date] => 2022-08-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25374 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17821295 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18254714 [patent_doc_number] => 20230081753 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-16 [patent_title] => APPLICATION OF SCFV PROTEIN, CAR GENE EXPRESSION VECTOR, CAR-T CELL AND APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 17/872131 [patent_app_country] => US [patent_app_date] => 2022-07-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3499 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17872131 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18093184 [patent_doc_number] => 20220411525 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-29 [patent_title] => BCMA AS A TARGET FOR T CELL REDIRECTING ANTIBODIES IN B CELL LYMPHOMAS [patent_app_type] => utility [patent_app_number] => 17/825123 [patent_app_country] => US [patent_app_date] => 2022-05-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13156 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17825123 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17982894 [patent_doc_number] => 20220348930 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-03 [patent_title] => CAR NKTs Expressing Artificial Micro RNA-Embedded shRNA for Downregulation of MHC Class I & II Expression [patent_app_type] => utility [patent_app_number] => 17/727528 [patent_app_country] => US [patent_app_date] => 2022-04-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27649 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17727528 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17897081 [patent_doc_number] => 20220306743 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-29 [patent_title] => COMBINATION OF CTLA4 AND PD1/PDL1 ANTIBODIES FOR TREATING CANCER [patent_app_type] => utility [patent_app_number] => 17/684211 [patent_app_country] => US [patent_app_date] => 2022-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 52949 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17684211 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17561729 [patent_doc_number] => 20220125878 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-28 [patent_title] => Compositions and Methods for Preventing the Interaction Between SARS-COV-2 and L-Sign [patent_app_type] => utility [patent_app_number] => 17/506370 [patent_app_country] => US [patent_app_date] => 2021-10-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11732 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17506370 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17258559 [patent_doc_number] => 20210371544 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-02 [patent_title] => LOW-VISCOSITY ANTIGEN BINDING PROTEINS AND METHODS OF MAKING THEM [patent_app_type] => utility [patent_app_number] => 17/346156 [patent_app_country] => US [patent_app_date] => 2021-06-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18896 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -76 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17346156 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17198637 [patent_doc_number] => 20210338731 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-04 [patent_title] => Non-Signaling HIV Fusion Inhibitors And Methods Of Use Thereof [patent_app_type] => utility [patent_app_number] => 17/306613 [patent_app_country] => US [patent_app_date] => 2021-05-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32874 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17306613 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17258539 [patent_doc_number] => 20210371524 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-02 [patent_title] => ANTI-CD45 ANTIBODIES AND CONJUGATES THEREOF [patent_app_type] => utility [patent_app_number] => 17/244856 [patent_app_country] => US [patent_app_date] => 2021-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45138 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17244856 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17124475 [patent_doc_number] => 20210299243 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-30 [patent_title] => IL-10 INHIBITION FOR VACCINES AND IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 17/173118 [patent_app_country] => US [patent_app_date] => 2021-02-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30588 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17173118 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16868543 [patent_doc_number] => 20210162010 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-03 [patent_title] => TARGETED HUMAN-INTERFERON FUSION PROTEINS [patent_app_type] => utility [patent_app_number] => 17/171426 [patent_app_country] => US [patent_app_date] => 2021-02-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6795 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17171426 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17082133 [patent_doc_number] => 20210277139 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-09 [patent_title] => IFN-GAMMA-INDUCIBLE REGULATORY T CELL CONVERTIBLE ANTI-CANCER (IRTCA) ANTIBODY AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/169091 [patent_app_country] => US [patent_app_date] => 2021-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30800 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17169091 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16898987 [patent_doc_number] => 20210177903 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-17 [patent_title] => CAR T-CELLS FOR THE TREATMENT OF BONE METASTATIC CANCER [patent_app_type] => utility [patent_app_number] => 17/169021 [patent_app_country] => US [patent_app_date] => 2021-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15914 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17169021 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17272954 [patent_doc_number] => 20210379152 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-09 [patent_title] => METHODS AND COMPOSITIONS FOR TREATING PAIN [patent_app_type] => utility [patent_app_number] => 17/153165 [patent_app_country] => US [patent_app_date] => 2021-01-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19732 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17153165 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17914732 [patent_doc_number] => 20220317127 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-06 [patent_title] => METHOD AND COMPOSITIONS FOR PREDICTING ANTI-CANCER EFFICACY OF COMPOUNDS TARGETING APOPTOSIS PATHWAY [patent_app_type] => utility [patent_app_number] => 17/297188 [patent_app_country] => US [patent_app_date] => 2020-11-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22961 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -41 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17297188 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16541007 [patent_doc_number] => 20200407420 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-31 [patent_title] => HER-1, HER-3 AND IGF-1R COMPOSITIONS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/024158 [patent_app_country] => US [patent_app_date] => 2020-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19266 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17024158 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17342305 [patent_doc_number] => 20220008636 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-13 [patent_title] => APHERESIS TO REMOVE INTERFERING SUBSTANCES [patent_app_type] => utility [patent_app_number] => 16/926771 [patent_app_country] => US [patent_app_date] => 2020-07-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3313 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16926771 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16397308 [patent_doc_number] => 20200338166 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-29 [patent_title] => ANTI-TUMOR DRUG COMPOSITION AND POLYNUCLEOTIDE COMPOSITION [patent_app_type] => utility [patent_app_number] => 16/921969 [patent_app_country] => US [patent_app_date] => 2020-07-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4684 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16921969 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17482272 [patent_doc_number] => 20220089776 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-24 [patent_title] => THERAPEUTIC FACTOR XII ANTIBODY [patent_app_type] => utility [patent_app_number] => 17/297967 [patent_app_country] => US [patent_app_date] => 2019-11-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30694 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17297967 [rel_patent_id] =>[rel_patent_doc_number] =>)